China's drug regulator approved Jiangsu Hengrui Pharmaceutical's (SHA:600276, HKG:1276) injection for type 2 diabetes patients, according to a Saturday filing with the Shanghai bourse.
The noliglutide injection helps control blood sugar in patients with poor glycemic control, combined with other drugs, the filing said.